{"protocolSection": {"identificationModule": {"nctId": "NCT00086515", "orgStudyIdInfo": {"id": "0431-020"}, "secondaryIdInfos": [{"id": "Formally-B0604T2DMT"}, {"id": "2006_411"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)", "officialTitle": "A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy"}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-06-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2005-07-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-02-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2004-07-02", "studyFirstSubmitQcDate": "2004-07-02", "studyFirstPostDateStruct": {"date": "2004-07-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-19", "resultsFirstSubmitQcDate": "2010-11-19", "resultsFirstPostDateStruct": {"date": "2010-12-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-03-31", "lastUpdatePostDateStruct": {"date": "2017-05-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type II"], "keywords": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 701, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin 100 mg", "type": "EXPERIMENTAL", "description": "The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.", "interventionNames": ["Drug: Sitagliptin (MK0431)", "Drug: Metformin", "Drug: Pioglitazone"]}, {"label": "Placebo / Glipizide 5 mg", "type": "PLACEBO_COMPARATOR", "description": "The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.", "interventionNames": ["Drug: Placebo/Glipizide 5 mg", "Drug: Metformin", "Drug: Pioglitazone"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin (MK0431)", "description": "Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104", "armGroupLabels": ["Sitagliptin 100 mg"], "otherNames": ["MK0431", "sitagliptin phosphate", "Januvia"]}, {"type": "DRUG", "name": "Placebo/Glipizide 5 mg", "description": "Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)", "armGroupLabels": ["Placebo / Glipizide 5 mg"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)", "armGroupLabels": ["Placebo / Glipizide 5 mg", "Sitagliptin 100 mg"]}, {"type": "DRUG", "name": "Pioglitazone", "description": "Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \\[Phase A\\], from Visit 5 (Week 6) to Visit 8 (Week 24)", "armGroupLabels": ["Placebo / Glipizide 5 mg", "Sitagliptin 100 mg"], "otherNames": ["ACTOS"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C (A1C) at Week 24", "description": "A1C is measured as a percent. Thus, this change from\n\nbaseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Baseline and Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change from baseline at Week 24 is defined as FPG at\n\nWeek 24 minus FPG at Week 0.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24", "description": "Change from baseline at Week 24 is defined as PMG at Week 24 minus PMG at Week 0.", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with type 2 diabetes mellitus", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "17130197", "type": "BACKGROUND", "citation": "Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006 Dec;29(12):2638-43. doi: 10.2337/dc06-0706."}, {"pmid": "18476982", "type": "BACKGROUND", "citation": "Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12."}], "availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/policies-perspectives.html"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 18-78 years of age with type 2 diabetes mellitus with inadequate glycemic control (hemoglobin A1C \\[A1C\\] \u22657% and \u226410%) on stable doses of metformin (\u22651500 mg/day) were eligible to enter the 104-week study.", "recruitmentDetails": "Primary therapy Period: 13-Jul-2004 through 02-Feb-2007 (for the 2-year Phase A and B periods); 100 study centers worldwide. (46 sites in the United States, 25 sites in 11 countries in Europe, and 29 sites in 13 countries in the rest of the world).", "groups": [{"id": "FG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo."}, {"id": "FG001", "title": "Placebo / Glipizide 5 mg", "description": "The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral\n\ntablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase\n\nB (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with\n\noral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated,\n\nin a blinded fashion, to a maximum dose of 15 mg/day."}], "periods": [{"title": "Phase A (Weeks 0-24)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "464"}, {"groupId": "FG001", "numSubjects": "237"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "415"}, {"groupId": "FG001", "numSubjects": "192"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "45"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Patient Moved", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Protocol-Spec lab discon criteria", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Poor compliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Patient needed prohibited treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Personal Circumstance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Phase A to Phase B Transition Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "415"}, {"groupId": "FG001", "numSubjects": "192"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "391"}, {"groupId": "FG001", "numSubjects": "164"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "28"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Patient received Phase A rescue therapy", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "Protocol-Spec lab discon criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Poor compliance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Patient needed prohibited treatment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Phase B (Weeks 24-104)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "391"}, {"groupId": "FG001", "numSubjects": "164"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "201"}, {"groupId": "FG001", "numSubjects": "109"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "190"}, {"groupId": "FG001", "numSubjects": "55"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "94"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Patient Moved", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol-Specific discontinuation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Protocol-Specific lab discon criteria", "reasons": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Patient Died", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Patient needed prohibited treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Personal Circumstance", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Discontinued in error", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo."}, {"id": "BG001", "title": "Placebo / Glipizide 5 mg", "description": "The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral\n\ntablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase\n\nB (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with\n\noral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated,\n\nin a blinded fashion, to a maximum dose of 15 mg/day."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "464"}, {"groupId": "BG001", "value": "237"}, {"groupId": "BG002", "value": "701"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.4", "spread": "10.4"}, {"groupId": "BG001", "value": "54.7", "spread": "9.7"}, {"groupId": "BG002", "value": "54.5", "spread": "10.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "205"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "301"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "259"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "400"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "293"}, {"groupId": "BG001", "value": "159"}, {"groupId": "BG002", "value": "452"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "45"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "100"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "75"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "29"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170.2", "spread": "40.2"}, {"groupId": "BG001", "value": "174.1", "spread": "42.0"}, {"groupId": "BG002", "value": "171.5", "spread": "41.3"}]}]}]}, {"title": "Hemoglobin A1C (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.0", "spread": "0.8"}, {"groupId": "BG001", "value": "8.0", "spread": "0.8"}, {"groupId": "BG002", "value": "8.0", "spread": "0.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C (A1C) at Week 24", "description": "A1C is measured as a percent. Thus, this change from\n\nbaseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 24, the last non-baseline observed measurement was carried forward to Week 24.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo."}, {"id": "OG001", "title": "Placebo / Glipizide 5 mg", "description": "The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral\n\ntablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase\n\nB (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with\n\noral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated,\n\nin a blinded fashion, to a maximum dose of 15 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "453"}, {"groupId": "OG001", "value": "224"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.67", "lowerLimit": "-0.77", "upperLimit": "-0.57"}, {"groupId": "OG001", "value": "-0.02", "lowerLimit": "-0.15", "upperLimit": "0.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, prior AHA status (not on AHA, on monotherapy oral AHA, or on metformin-based oral combination AHA), and baseline A1C", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.77", "ciUpperLimit": "-0.53"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change from baseline at Week 24 is defined as FPG at\n\nWeek 24 minus FPG at Week 0.", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 24, the last non-baseline observed measurement was carried forward to Week 24.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo."}, {"id": "OG001", "title": "Placebo / Glipizide 5 mg", "description": "The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral\n\ntablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase\n\nB (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with\n\noral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated,\n\nin a blinded fashion, to a maximum dose of 15 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "454"}, {"groupId": "OG001", "value": "226"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.9", "lowerLimit": "-21.5", "upperLimit": "-12.3"}, {"groupId": "OG001", "value": "8.5", "lowerLimit": "2.9", "upperLimit": "14.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, prior AHA status (not on AHA, on monotherapy oral AHA, or on metformin-based oral combination AHA), and baseline FPG", "paramType": "Mean Difference (Final Values)", "paramValue": "-25.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-31.0", "ciUpperLimit": "-19.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24", "description": "Change from baseline at Week 24 is defined as PMG at Week 24 minus PMG at Week 0.", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 24, the last non-baseline observed measurement was carried forward to Week 24.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo."}, {"id": "OG001", "title": "Placebo / Glipizide 5 mg", "description": "The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral\n\ntablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase\n\nB (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with\n\noral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated,\n\nin a blinded fashion, to a maximum dose of 15 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "387"}, {"groupId": "OG001", "value": "182"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-62.0", "lowerLimit": "-70.2", "upperLimit": "-53.8"}, {"groupId": "OG001", "value": "-11.4", "lowerLimit": "-21.7", "upperLimit": "-1.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, prior AHA status (not on AHA, on monotherapy oral AHA, or on metformin-based oral combination AHA), and baseline 2-hour PMG", "paramType": "Mean Difference (Final Values)", "paramValue": "-50.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-60.5", "ciUpperLimit": "-40.8"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Weeks 0-104", "description": "Patients received rescue medication if they met specific glycemic goals. Serious Adverse Events (SAEs) include events that occurred either before or after receiving rescue medication. Other Adverse Events (AEs) only includes those AEs that occurred prior to a patient receiving rescue medication.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.", "seriousNumAffected": 54, "seriousNumAtRisk": 464, "otherNumAffected": 210, "otherNumAtRisk": 464}, {"id": "EG001", "title": "Placebo / Glipizide 5 mg", "description": "The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral\n\ntablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase\n\nB (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with\n\noral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated,\n\nin a blinded fashion, to a maximum dose of 15 mg/day.", "seriousNumAffected": 21, "seriousNumAtRisk": 237, "otherNumAffected": 124, "otherNumAtRisk": 237}], "seriousEvents": [{"term": "Acute Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Angina Unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Cardiac Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Myocardial Ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Papilloedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Abdominal Strangulated Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Duodenal Ulcer Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Inguinal Hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Reflux Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Small Intestinal Obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Upper Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Hernia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Non-Cardiac Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 237}]}, {"term": "Biliary Colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Cholangitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Hepatic Failure", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Abdominal Wall Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Bronchitis Acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Helicobacter Gastritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Infected Epidermal Cyst", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Liver Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Lobar Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Meningitis Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Perirectal Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Pneumonia Primary Atypical", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Postoperative Wound Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Gun Shot Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Head Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Joint Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Polytraumatism", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Post Procedural Haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Tendon Rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Traumatic Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Blood Creatine Phosphokinase Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Blood Glucose Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "B-Cell Lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Basal Cell Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Bladder Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Clear Cell Carcinoma Of The Kidney", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Follicular Thyroid Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Hepatic Neoplasm Malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Lung Neoplasm Malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Ovarian Adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Pancreatic Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Papillary Thyroid Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Squamous Cell Carcinoma Of Skin", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Carotid Artery Stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Ischaemic Stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Loss Of Consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Subarachnoid Haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Transient Ischaemic Attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Calculus Ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Nocturia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Renal Colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Renal Failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Pelvic Haematoma", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Acute Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Tracheal Stenosis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 237}]}, {"term": "Finger Amputation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Arteriosclerosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}, {"term": "Leriche Syndrome", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 237}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 237}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 237}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 37, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 237}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 41, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 237}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 49, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 237}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 237}]}, {"term": "Blood Glucose Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 237}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 237}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 237}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 237}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (9.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 464}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 237}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type II", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000005913", "term": "Glipizide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M9023", "name": "Glipizide", "asFound": "Xylocaine", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}